COMP <GO>
COLL vs ABBV // FREE CASH FLOW YIELD
Collegium Pharmaceutical Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: COLL 5
— ABBV 6
■ METRIC PARITY
LAST: $24.03 (+3.44%) • MKT CAP: $782.3M
fcf-yield
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COLL VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COLL | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.30% | 70.20% | -10.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 29.00% | +56.00 | COLL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.0x | 33.3x | -30.30 | COLL | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | — | 3.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 23.00% | 24.60% | -1.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 8.10% | 6.90% | +1.20 | COLL | /net-margins <GO> |
| Revenue Growth (YoY) | 23.60% | 8.60% | +15.00 | COLL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.27 | 5.33 | -4.06 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 65.1 | -8.20 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.4x | 113.1x | -102.70 | COLL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $782.3M | $513.86B | -$513.08B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COLL REV | ABBV REV | COLL GROSS % | ABBV GROSS % | COLL FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $780.6M | $61.16B | 59.3% | 70.2% | $327.6M | $17.82B |
| FY 2024 | $631.4M | $56.33B | 59.8% | 70.0% | $203.3M | $17.83B |
| FY 2023 | $566.8M | $54.32B | — | — | $274.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COLL // BETA —
ABBV // BETA 1.15